Australia markets open in 7 hours 44 minutes

Soleno Therapeutics, Inc. (SLNO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.3465+0.0126 (+3.77%)
As of 10:15AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.3339
Open0.3600
Bid0.3380 x 800
Ask0.4059 x 800
Day's range0.3300 - 0.3600
52-week range0.2720 - 3.3600
Volume18,964
Avg. volume271,193
Market cap27.653M
Beta (5Y monthly)0.31
PE ratio (TTM)N/A
EPS (TTM)-0.3880
Earnings date01 Mar 2022 - 07 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.00
  • GlobeNewswire

    Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

    REDWOOD CITY, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update following recent interactions with the U.S. Food and Drug Administration (FDA) regarding the development of once-daily DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS). On January 20, 2022, the

  • GlobeNewswire

    Soleno Therapeutics to Participate in the LifeSci Partners 11th Annual Corporate Access Event

    REDWOOD CITY, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a panel discussion during the LifeSci Partners 11th Annual Corporate Access Event. Details for the panel discussions are below: Title:Patient Advocacy: Honing the Skill for Crossover Communicat

  • Zacks

    Down 13.9% in 4 Weeks, Here's Why Soleno Therapeutics, Inc. (SLNO) Looks Ripe for a Turnaround

    Soleno Therapeutics, Inc. (SLNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.